Clinical trial
LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients
NCT02121925 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients
- Lead sponsor
- Myriad Genetic Laboratories, Inc.
- Phase
- Observational
- Overall status
- Terminated
- Start date
- May 31, 2014
- Completion date
- July 31, 2017
- Enrollment
- 227 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung adenocarcinoma, lung cancer, nsclc